FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 344:424-429 February 8, 2001 Number 6 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Methanol poisoning may result in metabolic acidosis, blindness, and death. The inhibition of alcohol dehydrogenase is fundamental to the treatment of methanol poisoning. We performed a multicenter study to evaluate fomepizole, an inhibitor of alcohol dehydrogenase, in the treatment of patients with methanol poisoning.

Methods We administered intravenous fomepizole to 11 consecutive patients who presented with methanol poisoning at a participating center. Serial clinical and laboratory studies, including measurements of plasma formic acid and fomepizole, were performed. The outcomes measured were the preservation of visual acuity, the resolution of metabolic acidosis, the inhibition of formic acid production, the achievement of therapeutic plasma concentrations of fomepizole with the dosing regimen, residual illness or disability, and death.

Results Plasma formic acid concentrations were detectable in eight patients, and these concentrations were closely correlated with the initial arterial pH values (r=0.92, P<0.001). In response to fomepizole, plasma formic acid concentrations fell and metabolic abnormalities resolved in all patients. Nine patients survived. Seven patients initially had visual abnormalities, but at the end of the trial no surviving patient had any detectable visual deficits related to methanol poisoning. Fomepizole had few adverse effects. The two patients who died had anoxic brain injury that was present at the time of enrollment. During treatment, methanol had an elimination half-life of 54 hours.

Conclusions Fomepizole appears to be safe and effective in the treatment of methanol poisoning.

Source Information

From Toxicology Associates (J.B., S.P., K.K.), the Section of Clinical Pharmacology and Toxicology (J.B., S.P.), the Division of Emergency Medicine (J.B., K.K.), and the Section of Pediatric Pharmacology (J.B., K.K.), University of Colorado Health Sciences Center, Denver; the Department of Pharmacology, Louisiana State University Medical Center, Shreveport (K.M.); and the Department of Emergency Medicine, University of Massachusetts Medical Center, Worcester (C.A.).

Address reprint requests to Dr. Brent at Toxicology Associates, 2555 S. Downing, Suite 260, Denver, CO 80210, or at jeffrey.brent{at}uchsc.edu.

Full Text of this Article

This article has been cited by other articles:

• Schep, L. J, Slaughter, R. J, Vale, J A., Beasley, D M. G (2009). A seaman with blindness and confusion. BMJ 339: b3929-b3929 [Full Text]  
• Brent, J. (2009). Fomepizole for Ethylene Glycol and Methanol Poisoning. NEJM 360: 2216-2223 [Full Text]  
• Al aseri, Z., Altamimi, S. (2009). Keeping a high index of suspicion: lessons learned in the management of methanol ingestion. BMJ Case Reports 2009: bcr0920081013-bcr0920081013 [Abstract] [Full Text]  
• Bestic, M., Blackford, M., Reed, M. (2009). Fomepizole: A Critical Assessment of Current Dosing Recommendations. J Clin Pharmacol 49: 130-137 [Abstract] [Full Text]  
• Schmidt, G. A. (2009). Acid-Base Disorders. ACCP Crit Care Med Brd Rev 20: 413-424 [Full Text]  
• Hovda, K., Jacobsen, D (2008). Expert opinion: fomepizole may ameliorate the need for hemodialysis in methanol poisoning. Hum Exp Toxicol 27: 539-546 [Abstract]  
• Kraut, J. A., Kurtz, I. (2008). Toxic Alcohol Ingestions: Clinical Features, Diagnosis, and Management. CJASN 3: 208-225 [Abstract] [Full Text]  
• Betten, D. P., Vohra, R. B., Cook, M. D., Matteucci, M. J., Clark, R. F. (2006). Antidote Use in the Critically Ill Poisoned Patient. J Intensive Care Med 21: 255-277 [Abstract]  
• Takayesu, J. K., Bazari, H., Linshaw, M. (2006). Case 7-2006 -- A 47-Year-Old Man with Altered Mental Status and Acute Renal Failure. NEJM 354: 1065-1072 [Full Text]  
• Hantson, P, Haufroid, V, Wallemacq, P (2005). Formate kinetics in methanol poisoning. Hum Exp Toxicol 24: 55-59 [Abstract]  
• Colianni, S., Ping, J., Fischer, P. R., Freese, D., Chan, K., Alkuraya, F. S. (2004). Index of Suspicion. Pediatr. Rev. 25: 289-294 [Full Text]  
• Kan, G., Jenkins, I., Rangan, G., Woodroffe, A., Rhodes, H., Joyce, D. (2003). Continuous haemodiafiltration compared with intermittent haemodialysis in the treatment of methanol poisoning. Nephrol Dial Transplant 18: 2665-2667 [Full Text]  
• Blondell, R. D., Dodds, H. N., Sexton, L. K. (2003). Ethanol in Hospital Formularies--Reply. JAMA 289: 2361-2361 [Full Text]  
• Mokhlesi, B., Leikin, J. B., Murray, P., Corbridge, T. C. (2003). Adult Toxicology in Critical Care: Part II: Specific Poisonings. Chest 123: 897-922 [Full Text]  
• Cursiefen, C, Bergua, A (2002). Acute bilateral blindness caused by accidental methanol intoxication during fire "eating". Br J Ophthalmol 86: 1064-1065 [Full Text]  
• Chu, J., Wang, R. Y., Hill, N. S. (2002). Update in Clinical Toxicology. Am. J. Respir. Crit. Care Med. 166: 9-15 [Full Text]  
• Jones, A L, Dargan, P I (2002). Advances, challenges, and controversies in poisoning.. Emerg. Med. J. 19: 190-192 [Full Text]  
• Brown, M. J., Shannon, M. W., Woolf, A., Boyer, E. W. (2001). Childhood Methanol Ingestion Treated With Fomepizole and Hemodialysis. Pediatrics 108: e77-77 [Abstract] [Full Text]  
• (2001). Fomepizole Is Safe and Effective for Methanol Poisoning. JWatch Emergency Med. 2001: 2-2 [Full Text]